Pipeline
Pipeline
Kriya is developing a portfolio of one-time gene therapies to address common chronic diseases. Our current pipeline includes three main therapeutic areas:
| Therapeutic Area | Program | Disease | Mechanism | Discovery | Research | IND-Enabling | Clinical |
|---|---|---|---|---|---|---|---|
| Ophthalmology | |||||||
| KRIYA-825 | Geographic Atrophy | Anti-C3 and C5 | |||||
| KRIYA-586 | Thyroid Eye Disease | Anti-IGF1R Antibody | |||||
| KRIYA-296 | Undisclosed | Undisclosed | |||||
| Metabolic | |||||||
| KRIYA-839 | Type 1 Diabetes | Insulin & Glucokinase | |||||
| KRIYA-497 | MASH | FGF21 | |||||
| KRIYA-652 | Undisclosed | Undisclosed | |||||
| Neurology | |||||||
| KRIYA-748 | Trigeminal Neuralgia | Engineered Ion Channel | |||||
| KRIYA-382 | Focal Epilepsy | Engineered Ion Channel | |||||
| KRIYA-454 | Undisclosed | Undisclosed | |||||
| Ophthalmology | |||
|---|---|---|---|
| Discovery | Research | IND-Enabling | Clinical |
| Geographic Atrophy | Anti-C3 and C5 | |||
KRIYA-825 |
|||
| Thyroid Eye Disease | Anti-IGF1R Antibody | |||
KRIYA-586 |
|||
| Undisclosed | Undisclosed | |||
KRIYA-296 |
|||
| Metabolic | |||
| Discovery | Research | IND-Enabling | Clinical |
| Type 1 Diabetes | Insulin & Glucokinase | |||
KRIYA-839 |
|||
| MASH | FGF21 | |||
KRIYA-497 |
|||
| Undisclosed | Undisclosed | |||
KRIYA-652 |
|||
| Neurology | |||
| Discovery | Research | IND-Enabling | Clinical |
| Trigeminal Neuralgia | Engineered Ion Channel | |||
KRIYA-748 |
|||
| Focal Epilepsy | Engineered Ion Channel | |||
KRIYA-382 |
|||
| Undisclosed | Undisclosed | |||
KRIYA-454 | |||
Kriya’s pipeline candidates are investigational and have not been approved as safe or effective by any regulatory health authority.
Ophthalmology
Metabolic
Neurology
